CarBel for antibody-mediated rejection after kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant (from a living or deceased donor).
- You have been diagnosed with antibody-mediated rejection (a type of rejection where your immune system attacks the new kidney).
- You have been exposed to the Epstein-Barr virus (EBV) in the past.
- Your kidney function is at a certain level (eGFR of at least 30).
- Your heart is healthy enough (with an LVEF of at least 40%).
- You are up to date on your vaccinations, have a negative TB test, and have no recent serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.